Uroloxía
Servizo
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (11)
2023
-
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126
-
Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply
Actas Urologicas Espanolas
-
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial
European urology oncology, Vol. 6, Núm. 1, pp. 58-66
2020
-
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163
2019
-
Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin
Actas Urologicas Espanolas, Vol. 43, Núm. 3, pp. 143-150
2017
-
Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group
Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367
2016
-
Expert opinion about the use of transdermic oxybutynin in Spain for the treatment of adult overactive bladder
Archivos Espanoles de Urologia, Vol. 69, Núm. 9, pp. 613-620
-
Influence of demographic and tumour variables on prostate cancer treatment with curative intent in Spain. Results of the 2010 national prostate cancer registry
Actas Urologicas Espanolas, Vol. 40, Núm. 8, pp. 485-491
2014
2013
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2004
-
Evaluation of the Transurethral Ethanol Ablation of the Prostate (TEAP) for symptomatic benign prostatic hyperplasia (bph): A european multi-center evaluation
European Urology, Vol. 46, Núm. 4, pp. 496-502